Echoes of ancient wisdom and synergistic strategies invigorate the fight against liver fibrosis

Table 1 Epistemic evolution in antifibrotic drug discovery

Feature	Reductionist paradigm (current)	Systems pharmacology paradigm (proposed)	Mechanistic rationale
Therapeutic philosophy	Linear monotargeting: High-affinity blockade of isolated molecular targets	Network perturbation: Combinatorial modulation of topological hubs	Topological vulnerability: Fibrotic networks are scale-free; simultaneous multi-node perturbation collapses topology
System response	Hydra effect (compensatory rerouting): Dynamic activation of alternative signaling pathways to sustain fibrogenesis	Synergistic attenuation: Concurrent, low-grade dampening of parallel pathways prevents feedback loop activation	Biological robustness: Monotherapy triggers homeostatic compensation; combinatorial logic disrupts system
Safety profile	High-dose toxicity: Requires high receptor occupancy, risking physiological homeostasis disruption	Improved therapeutic index: Efficacy achieved via additive/synergistic interactions at sub-toxic concentrations	Pharmacodynamic synergy: Constituents exert entourage effects
Developmental focus	Affinity-based optimization: IC50 and molecular selectivity	Phenotype-driven efficacy: Maximizing phenotypic reversion	Functional bioequivalence: Shifts validation metrics from chemical purity to bioactivity linked network modulation